AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC lifted its position in shares of AstraZeneca PLC (NASDAQ:AZNFree Report) by 22.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,299 shares of the company’s stock after purchasing an additional 1,152 shares during the period. Kingsview Wealth Management LLC’s holdings in AstraZeneca were worth $427,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Capital International Investors lifted its position in shares of AstraZeneca by 0.6% during the 2nd quarter. Capital International Investors now owns 38,339,765 shares of the company’s stock worth $2,740,406,000 after purchasing an additional 211,055 shares during the last quarter. Jennison Associates LLC raised its stake in AstraZeneca by 5.2% during the 3rd quarter. Jennison Associates LLC now owns 22,946,504 shares of the company’s stock worth $1,553,937,000 after acquiring an additional 1,139,295 shares in the last quarter. Morgan Stanley raised its stake in AstraZeneca by 18.0% during the 4th quarter. Morgan Stanley now owns 10,222,597 shares of the company’s stock worth $693,092,000 after acquiring an additional 1,561,194 shares in the last quarter. Capital World Investors raised its stake in AstraZeneca by 9.7% during the 2nd quarter. Capital World Investors now owns 9,146,004 shares of the company’s stock worth $654,490,000 after acquiring an additional 809,779 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in AstraZeneca by 2.2% during the 2nd quarter. Fisher Asset Management LLC now owns 8,932,907 shares of the company’s stock worth $639,328,000 after acquiring an additional 189,382 shares in the last quarter. 15.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Morgan Stanley assumed coverage on shares of AstraZeneca in a research note on Tuesday, January 23rd. They set an “overweight” rating on the stock. HSBC began coverage on shares of AstraZeneca in a research note on Monday, December 18th. They issued a “buy” rating on the stock. Finally, Jefferies Financial Group lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.00.

Get Our Latest Report on AZN

AstraZeneca Trading Up 2.9 %

Shares of AstraZeneca stock opened at $67.04 on Wednesday. AstraZeneca PLC has a 52-week low of $61.73 and a 52-week high of $76.56. The company has a quick ratio of 0.60, a current ratio of 0.79 and a debt-to-equity ratio of 0.60. The company’s 50-day simple moving average is $66.53 and its 200-day simple moving average is $66.80. The firm has a market cap of $207.85 billion, a price-to-earnings ratio of 35.28, a price-to-earnings-growth ratio of 1.16 and a beta of 0.52.

AstraZeneca (NASDAQ:AZNGet Free Report) last issued its quarterly earnings results on Wednesday, November 8th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.03. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $11.55 billion. AstraZeneca had a net margin of 13.10% and a return on equity of 30.30%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.84 earnings per share. As a group, equities research analysts anticipate that AstraZeneca PLC will post 3.66 earnings per share for the current year.

AstraZeneca Company Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Articles

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.